TY - JOUR T1 - Vagus Nerve and Stomach Synucleinopathy in Parkinson’s Disease, Incidental Lewy Body Disease and Normal Elderly Subjects: Evidence Against the “Body-First” Hypothesis JF - medRxiv DO - 10.1101/2020.09.29.20204248 SP - 2020.09.29.20204248 AU - Thomas G. Beach AU - Charles H. Adler AU - Lucia I. Sue AU - Holly A. Shill AU - Erika Driver-Dunckley AU - Shyamal H. Mehta AU - Anthony J. Intorcia AU - Michael J. Glass AU - Jessica E. Walker AU - Richard Arce AU - Courtney M. Nelson AU - Geidy E. Serrano Y1 - 2020/01/01 UR - http://medrxiv.org/content/early/2020/09/30/2020.09.29.20204248.abstract N2 - Braak and others have proposed that Lewy-type α-synucleinopathy (aSyn) in Parkinson’s disease (PD) may arise from an exogenous pathogen that passes across the gastric mucosa and then is retrogradely transported up the vagus nerve to the medulla. We tested this “body-first” hypothesis by immunohistochemically staining stomach and vagus nerve tissue from an autopsy series of 111 normal elderly subjects (no brain aSyn), 33 with incidental Lewy body disease (ILBD) (brain aSyn without clinical parkinsonism or dementia) and 53 with PD. Median disease duration for the PD group was 13 years. Vagus nerve samples were taken adjacent to the carotid artery in the neck. Stomach samples were taken from the gastric body, midway along the greater curvature. Formalin-fixed paraffin-embedded sections were immunohistochemically stained for α-synuclein phosphorylated at serine-129. In the vagus nerve none of the 111 normal subjects had aSyn in the vagus, while 12/26 ILBD (46%) and 32/36 PD (89%) subjects were aSyn-positive. In the stomach none of the 102 normal subjects had aSyn while 5/30 (17%) ILBD and 42/52 (81%) of PD subjects were aSyn-positive. As there was no aSyn in the vagus nerve or stomach of subjects without brain aSyn, these results support initiation of aSyn in the brain. The presence of aSyn in the vagus nerve and stomach of a subset of ILBD cases indicates that progression of synucleinopathy to the peripheral nervous system may occur at preclinical stages of Lewy body disease.Competing Interest StatementThe authors have declared no competing interest.Funding StatementNational Institute of Neurological Disorders and Stroke U24 NS072026. National Institute on Aging P30 AG19610. Arizona Department of Health Services. Arizona Biomedical Research Commission. Michael J Fox Foundation.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Western Institutional Review Board, Puyallup, WAAll necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll data referred to in the manuscript is available on request from the corresponding author. ER -